Prostate Biopsy Collaborative Group (PBCG): The PBCG was founded in 2009 to prospectively collect prostate cancer risk factor and biopsy outcome data from multiple international urological centers in order to develop contemporary prostate cancer risk prediction tools. Development of such tools requires novel statistical methods and models for integrating multiple data types from heterogeneous centers, as well as recalibration to accommodate new data and outcomes in response to a continuously evolving prostate cancer clinical landscape. These tools are made publicly available for patient-clinician decision-making, the most recent one can be found here: https://riskcalc.org/PBCG/.

Bias correction procedures for external validation: Data from the large North American Selenium and Vitamin E Cancer Prevention Trial (SELECT) and the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) are used to develop procedures for correcting risk prediction validation procedures for differing eligibility criteria (selection bias) and biopsy protocols (verification bias).

Spatio-temporal prediction error assessment: Visualization and quantification methodology are developed for risk forecasting models that vary in space and time, such as the intertwined processes of infection and death from COVID-19.